{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:08:46Z","timestamp":1780308526804,"version":"3.54.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.7759\/cureus.110026","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:47:45Z","timestamp":1780307265000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report"],"prefix":"10.7759","author":[{"given":"Shohei","family":"Otsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Iwashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021, 397:375-86. 10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell DA","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C, et al.. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021, 22:1530-40. 10.1016\/S1470-2045(21)00471-X","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin DW","year":"2024","unstructured":"Dumoulin DW, Douma LH, Hofman MM, et al.. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma. Lung Cancer. 2024, 187:107440. 10.1016\/j.lungcan.2023.107440","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann MD","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, et al.. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019, 381:2020-31. 10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja L","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017, 28:2377-85. 10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.02.012","article-title":"Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer","volume":"21","author":"Miyawaki T","year":"2020","unstructured":"Miyawaki T, Kenmotsu H, Mori K, et al.. Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2020, 21:e405-14. 10.1016\/j.cllc.2020.02.012","journal-title":"Clin Lung Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121557","article-title":"Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress","volume":"14","author":"Perrino M","year":"2023","unstructured":"Perrino M, De Vincenzo F, Cordua N, Borea F, Aliprandi M, Santoro A, Zucali PA. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress. Front Immunol. 2023, 14:1121557. 10.3389\/fimmu.2023.1121557","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada M","year":"2019","unstructured":"Okada M, Kijima T, Aoe K, et al.. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019, 25:5485-92. 10.1158\/1078-0432.CCR-19-0103","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/425286-long-term-disease-control-with-second-line-nivolumab-monotherapy-in-malignant-pleural-mesothelioma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:47:46Z","timestamp":1780307266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/425286-long-term-disease-control-with-second-line-nivolumab-monotherapy-in-malignant-pleural-mesothelioma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.110026","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}